


*

B12 (*Vit B₁₂*) :
(/ *mg/kg*)
HPLC *SGOT SGPT ALP*
(*P* < / / ± / $\mu\text{mol/L}$ / ± / $\mu\text{mol/L}$:) :
(*ALP*) (*Triglyceride Cholesterol LDL*)
() *B12*

(/)
 (/) .()
 / (Hcy)
 Hcy .
 % / % / Vit B₁₂
 Hcy
 .()
 TG (Vit B₆)
 HDL LDL Hcy Cholesterol .()
 Vit B₁₂ (ALP SGOT SGPT) B₁₂ B₆)
) ()
 .() Hcy
 (Homocysteinemia)
 Hcy
) %
 () / ± / A .()
 ()
 NSAID .()
 Hcy
 Hcy
 Schulpis
 Hcy
 Hcy
 .()



Hcy		Hcy		(/ mg.kg/day)	
/	/	/	/	(Hcy)	
/	/	/	/	SGPT)	B ₁₂
/	/	/	/	TG)	(ALP SGOT
/	/	/	/		(HDL LDL Cholesterol
/	/	/	/) HPLC	
/	/	/	/	(Hcy	
/	/	/	/	RIA	B ₁₂
/	/	/	/	paired T-test	
/	/	/	/	()
Confidence Interval : CI *				P < /	
Hcy		Hcy			
() B ₁₂			
(correlation)		SGPT, SGOT			Hcy
()				()	()
				(ALP)	
(ISO)				(HDL
				()	
				(ALP)	


r < /		Hcy
r < /	Vit B12	Hcy
r < /		Hcy
r < /	Vit B12	Hcy
r = /	SGOT	(Hcy)
r = /	SGPT	(Hcy)

(ISO)			
()	HDL	LDL	VLDL

P value			
P < /	/ ± /	/ ± /	Hcy (μmol/L)
P < /	/ ± /	/ ± /	SGOT (μ/ml)
P < /	/ ± /	/ ± /	SGPT(μ/ml)
NS *	/ ± /	/ ± /	Alp (μ/l)
P < /	/ ± /	/ ± /	Chol (mg/dl)
P < /	± /	/ ± /	TG (mg/dl)
P < /	/ ± /	/ ± /	LDL(mg/dl)
P < /	/ ± /	/ ± /	HDL(mg/dl)

Not Significant : NS *

Hcy Isotretinon .
 () B₁₂
 . ()
 () SGOT SGPT
 . ()
 Schulpis Isotretinoin (Hcy)
 Hcy Hcy
 Hcy
) Methionin – loading test ()
 (B
 B₆ Hcy
 Hcy ()
 Isotretinoin Methionin loading test
) Hcy B
 (… Vit B₆ Hcy
 B₁₂ Schulpis . ()
 () B₆ Hcy
 . ()
 subclinical Metionin loading test
 () Isotretinoin
 B () Hcy
 (CAD) Hcy
 Isotretinoin schulpis
 B
 Hcy
 Hcy () ISO



REFERENCES

1. Simpson NB, Cunliffe WJ. Disorder of the sebaceous glands. Rook's textbook of dermatology. 7th ed. Uk: Blackwell. 2004.
2. Alcalay J, Landau M, Zueker A. Analysis of laboratory data in acne patients treatment with isotretinoin is there really a need to perform routine laboratory test? *J Derm Treat* 2001; 12(1): 9-12.
3. Phillips MD. Interrelated risk factor for venous thrombosis. *Circulation* 1989; 79: 1180-8.
4. Voutilainen S, Lakka TA, Porkkala-Sarataho E, Rissanen T, Kaplan GA, Salonen JT. Low serum folate concentrations are associated with disease risk factor study. *Eur J Clin Nutr* 2000; 54: 424-8.
5. Amichai B, Grunwald MH. Isotretinoine in dermatology. *J Dermatol Treat* 1998; 11: 219-40.
6. Schulips KH, Karikas GA, Georgala S, Michas T. Elevated plasma Homocysteine levels in patients on isotretinoin therapy for cystic acne. *Int J Dermatol* 2001; 40(1): 33-6.
7. Chanson A, Cardinault N, Rock E, Martin JF, Souteyrand P, D'Incan M, et al. Decreased plasma folate concentration in young and elderly healthy subjects after a short-term supplementation with isotretinoin. *J Eur Acad Dermatol Venereol* 2008; 22(1): 94-100.
8. Christensen B, Refsum H, Vintermyr O, uleand PM. Homocysteine export from cells cultured in the presence of physiological or superfinous levels of methionine: Methionin loading of nontransformed, transformed, proliferating, and quiescent cells in culture. *J Cell Physiol* 1991; 146: 52-62.
9. Svardal AM, Djurhuus R, Refsum H. Deposition of homocysteine in rat hepatocytes and in nontransformed and malignant mouse embryo fibroblasts following exposure to inhibitors of S-adenosyl homocysteine catabolism. *Cancer Res* 1986; 46: 5095-100.
10. Schulp's KH, Gerogala S, Karikas GA, Michas T. The effect of isotretinoin on biotidinase activity. *Skin Pharmacol* 1999; 12: 28-33.
11. Pan charuniti N, Lewis CA. Plasma homocysteine, folate, and vitamin B12 concentrations and risk for early-onset coronary artery disease. *Am J Clin Nutr* 1994; 59(4): 940-8.
12. Ubbink JB, Vermak WJH, Becker PJ. Vitamin B12, Vitamin B6 and folate nutritional status in men with hyperhomocysteinemia. *Am J Clin Nutr* 1981; 57: 47-53.
13. Murua AL, Quintana I, Janson J, Batista M. Plasmatic homocysteine response to vitamin supplementation in elderly people. *Thromb Res* 2000; 100(6): 495-500.

-
14. Kang SS, Wand PW, Notusis M. Homocysteinemia due to folate deficiency. *Metabolism* 1987; 36(5): 458-62.

Archive of SID